Orchestrating the immune system for precision immunity

Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.

Like Comment
Page of
Go to the profile of Elicio Therapeutics

Elicio Therapeutics

CEO, Elicio Therapeutics

Elicio, based in Cambridge MA, is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to defeat cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, and vaccines for an array of aggressive cancers. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed by Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, in the Koch Institute of Cancer Research at the Massachusetts Institute of Technology.

No comments yet.